Table 1.

The Application of Baricitinib in Dermatology. vIGA-AD (0, 1): Validated Investigator’s Global Assessment of AD (Complete or Almost Complete Removal of Lesions)

Diseases	Signaling Pathway and Cytokines	Latest Trials	Effective Dose	Effects	Adverse Events
Atopic dermatitis (AD)	TH2axis, TH17/TH22/TH1;14 IL-14, IL-5, IL-13, IL-22, IL-3137	Randomized clinical trial Phase 337,38	Oral 2mg/4mg once daily38	11.4% for baricitinib 2mg and 16.8% for baricitinib 4 mg achieved vIGA-AD (0, 1) at week 16; 2 mg baricitinib group achieved EASI75 in week-1637,38	Nasopharyngitis, upper respiratory tract infections, and folliculitis37
Psoriasis	IL-23/Th17 axis15	Randomized clinical trial phase218	Oral 8mg/10mg once daily18	8mg or 10mg barbitinib group achieved index (PASI)-75 after 12 weeks18	No serious adverse events18
Vitiligo	CXCR3+ CD8+ T; IFN-γ21	Randomized clinical trial phase221	Oral 4mg once daily (no result yet)21	No result yet21	No result yet21
Alopecia areata (AA)	CD8 + NKG2D + T cells; IFN-γ, IL-15, IL-2, IL-722	Randomized clinical trial phase229	Oral 2mg/4mg once daily29	33.3% for baricitinib 2mg and 51.9% for baricitinib 4 mg achieved a severity of alopecia tool score of <20 at 36 weeks29	No serious adverse events29